Updated on 12 April 2012
One of the notable advances transforming the field of pharmacotherapy is biopharmaceuticals, which comprise therapies derived from biological sources such as living cells or animal tissues. As the large and complex molecules (mainly sugars, proteins, and nucleic acids) are easily denatured, or altered, with harsh handling and processing, in most cases, oral drug delivery fails to be an adoptable option. Further, the physical properties of many biologics, such as high viscosity and the necessity of injection of volumes up to 1 milliliter, are driving the market for improved drug delivery devices.
Innovation in drug delivery systems design is in a constant state of evolution as manufacturers strive to meet the ever-changing demand for safe, functional and user-friendly devices.
Drug delivery devices enable the treatment and prevention of a wide variety of diseases that include diabetes, cancer, autoimmune disorders and infectious diseases. Targeted delivery of the drug to the intended site is a key factor that is necessitating the development of various forms of drug delivery in order to reduce the systemic exposure of certain drugs, thereby, minimizing the side effects.
The current drug delivery device portfolio is filled with numerous non-invasive product candidates targeting a wide spectrum of disease indications. Devices targeting infectious diseases and cancer top the list, followed closely by autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, along with cardiovascular and hematology indications like heart failure, thrombosis, and anemia.